MBIO PE Ratio & Valuation,Is MBIO Overvalued — Intellectia
MBIO Relative Valuation
MBIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MBIO is overvalued; if below, it's undervalued.
Historical Valuation
Mustang Bio Inc(MBIO) is now in theFairzone, suggesting that its currentforward PSratio of0.00is consideredFairlycompared with the five-year average of-1.98.The fair price ofMustang Bio Inc(MBIO)is between--to--according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：1.20
Fair
-0.07
PE
1Y
3Y
5Y
Trailing
Forward
0.48
EV/EBITDA
Mustang Bio Inc. (MBIO) has a current EV/EBITDA of 0.48. The 5-year average EV/EBITDA is -0.31. The thresholds are as follows: Strongly Undervalued below -2.24, Undervalued between -2.24 and -1.27, Fairly Valued between 0.65 and -1.27, Overvalued between 0.65 and 1.61, and Strongly Overvalued above 1.61. The current Forward EV/EBITDA of 0.48 falls within the Historic Trend Line -Fairly Valued range.
0.48
EV/EBIT
Mustang Bio Inc. (MBIO) has a current EV/EBIT of 0.48. The 5-year average EV/EBIT is -0.63. The thresholds are as follows: Strongly Undervalued below -3.13, Undervalued between -3.13 and -1.88, Fairly Valued between 0.62 and -1.88, Overvalued between 0.62 and 1.87, and Strongly Overvalued above 1.87. The current Forward EV/EBIT of 0.48 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Mustang Bio Inc. (MBIO) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.
-0.18
P/OCF
Mustang Bio Inc. (MBIO) has a current P/OCF of -0.18. The 5-year average P/OCF is -1.34. The thresholds are as follows: Strongly Undervalued below -4.91, Undervalued between -4.91 and -3.13, Fairly Valued between 0.44 and -3.13, Overvalued between 0.44 and 2.23, and Strongly Overvalued above 2.23. The current Forward P/OCF of -0.18 falls within the Historic Trend Line -Fairly Valued range.
-0.18
P/FCF
Mustang Bio Inc. (MBIO) has a current P/FCF of -0.18. The 5-year average P/FCF is -1.30. The thresholds are as follows: Strongly Undervalued below -4.72, Undervalued between -4.72 and -3.01, Fairly Valued between 0.41 and -3.01, Overvalued between 0.41 and 2.12, and Strongly Overvalued above 2.12. The current Forward P/FCF of -0.18 falls within the Historic Trend Line -Fairly Valued range.
Mustang Bio Inc (MBIO) has a current Price-to-Book (P/B) ratio of 0.89. Compared to its 3-year average P/B ratio of 8.41 , the current P/B ratio is approximately -89.39% higher. Relative to its 5-year average P/B ratio of 5.71, the current P/B ratio is about -84.36% higher. Mustang Bio Inc (MBIO) has a Forward Free Cash Flow (FCF) yield of approximately -63.56%. Compared to its 3-year average FCF yield of -270.88%, the current FCF yield is approximately -76.54% lower. Relative to its 5-year average FCF yield of -181.02% , the current FCF yield is about -64.89% lower.
0.85
P/B
Median3y
8.41
Median5y
5.71
-63.56
FCF Yield
Median3y
-270.88
Median5y
-181.02
Competitors Valuation Multiple
The average P/S ratio for MBIO's competitors is 0.90, providing a benchmark for relative valuation. Mustang Bio Inc Corp (MBIO) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of MBIO increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of MBIO in the past 1 year is driven by Unknown.
Is Mustang Bio Inc (MBIO) currently overvalued or undervalued?
Mustang Bio Inc(MBIO)is now in theFairzone, suggesting that its currentforward PSratio of 0.00is consideredFairlycompared with the five-year average of-1.98.The fair price of Mustang Bio Inc(MBIO)is betweentoaccording to relative valuation methord.
What is Mustang Bio Inc (MBIO) fair value?
MBIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Mustang Bio Inc (MBIO) is between to according to relative valuation methord.
How does MBIO's valuation metrics compare to the industry average?
The average P/S ratio for MBIO's competitors is 0.90, providing a benchmark for relative valuation. Mustang Bio Inc Corp (MBIO) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Mustang Bio Inc (MBIO) as of Dec 16 2025?
As of Dec 16 2025, Mustang Bio Inc (MBIO) has a P/B ratio of 0.89. This indicates that the market values MBIO at 0.89 times its book value.
What is the current FCF Yield for Mustang Bio Inc (MBIO) as of Dec 16 2025?
As of Dec 16 2025, Mustang Bio Inc (MBIO) has a FCF Yield of -63.56%. This means that for every dollar of Mustang Bio Inc’s market capitalization, the company generates -63.56 cents in free cash flow.
What is the current Forward P/E ratio for Mustang Bio Inc (MBIO) as of Dec 16 2025?
As of Dec 16 2025, Mustang Bio Inc (MBIO) has a Forward P/E ratio of -0.07. This means the market is willing to pay $-0.07 for every dollar of Mustang Bio Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Mustang Bio Inc (MBIO) as of Dec 16 2025?
As of Dec 16 2025, Mustang Bio Inc (MBIO) has a Forward P/S ratio of 0.00. This means the market is valuing MBIO at $0.00 for every dollar of expected revenue over the next 12 months.
